FibroGen (FGEN) – Globe Newswire
-
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meetin
-
FibroGen Reports Third Quarter 2023 Financial Results
-
FibroGen to Report Third Quarter 2023 Financial Results
-
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
-
FibroGen Reports Second Quarter 2023 Financial Results
-
FibroGen Announces Leadership Transition
-
FibroGen to Report Second Quarter 2023 Financial Results
-
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
-
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
-
FibroGen to Present at Jefferies Global Healthcare Conference
-
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
-
FibroGen Reports First Quarter 2023 Financial Results
-
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
-
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
-
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
-
FibroGen to Report First Quarter 2023 Financial Results
-
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
-
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
-
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
-
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
-
FibroGen to Present at SVB Securities Global Biopharma Conference
-
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
-
FibroGen Reports Third Quarter 2022 Financial Results
-
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
-
FibroGen to Participate at Stifel 2022 Healthcare Conference
-
FibroGen to Report Third Quarter 2022 Financial Results
-
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic
-
FibroGen Reports Second Quarter 2022 Financial Results
-
FibroGen to Report Second Quarter 2022 Financial Results
-
FibroGen to Participate at William Blair Biotech Focus Conference 2022
-
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
-
FibroGen to Present at Jefferies Healthcare Conference
-
FibroGen Reports First Quarter 2022 Financial Results
-
FibroGen to Report First Quarter 2022 Financial Results
-
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
-
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
-
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
-
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
-
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
-
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
-
FibroGen Reports Third Quarter 2021 Financial Results
-
FibroGen to Present at Upcoming Investor Conferences
-
FibroGen to Report Third Quarter 2021 Financial Results
-
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
-
FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
-
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
-
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
-
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
-
FibroGen Reports Second Quarter 2021 Financial Results
-
FibroGen to Report Second Quarter 2021 Financial Results
Back to FGEN Stock Lookup
